Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs

Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration.  The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy.

Since its establishment in 2015, EyeCure has been deeply involved in the field of ophthalmic cell and gene therapy.  Its research and development focus on the development of human retinal pigment epithelial cells, corneal cells and mesenchymal stem cells, creating a new therapeutic field of using adult RPE cells to treat age-related macular degeneration and pigmentary degeneration.  Medicilon, as a one-stop preclinical biopharmaceutical comprehensive R&D service CRO, has also been deeply involved in the field of ophthalmic drugs for many years, and has established the "Medicilon Preclinical Ophthalmic Drug Research Platform" which can provide efficient, high-quality, and cost-effective drug discovery, pharmaceutical research, preclinical research services.

Medicilon Preclinical Ophthalmic Drug Development Platform
Help EyeCure to accelerate the development of new ophthalmic drugs 

Complementary advantages in resources and a high degree of compatibility in vision allow Medicilon and EyeCure to achieve two-way development.  In this collaboration, relying on Medicilon's one-stop biopharmaceutical preclinical research and development service platform, Medicilon will provide EyeCure with services including but not limited to drug discovery, pharmaceutical research, preclinical research and comprehensive projects to assist in the development of a new class 1 ophthalmology drug.